Eli Lilly and Co (NYSE:LLY) will report its third quarter 2025 earnings next Thursday, with Bank of America analysts closely watching how the company’s obesity and diabetes treatments are performing amid ongoing policy debates over US drug pricing.
The firm believes the drugmaker’s upcoming report could offer insight into the company’s key brands while highlighting broader industry trends affecting margins and growth.
Eli Lilly’s earnings call is expected to cover several key areas, including US drug pricing policies such as the Most Favored Nation (MFN) rule and Section 232 tariffs, as well as late-stage clinical updates for treatments like retatrutide TRIUMPH-4 and Novo Nordisk’s REDEFINE-4 trial.
The analysts also anticipate discussion of core brands, including Mounjaro and Zepbound, alongside the launch dynamics of newer therapies such as Kisunla for Alzheimer’s disease and Ebglyss for atopic dermatitis.
Bank of America sees Eli Lilly as well-positioned in its key therapeutic areas, noting “Eli Lilly undisputably remains in pole position in obesity.”
The analysts repeated their ‘Buy’ rating on the stock and $900 price target, implying upside of about 12% at their time of writing.
“Admittedly, there are lots of moving parts to the Eli Lilly story, and Eli Lilly is not a stock for the faint at heart, given binary event risk.”
Wall Street analysts on average expect Eli Lilly to report revenue of $16 billion, up 40% year-over-year, and earnings per share of $6.30, a surge of more than 430% from the year-ago quarter.